|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 89.34 | 104.64 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | -3.85 | -2.03 | -4.19 | -2.36 | -1.34 | CEPS(Rs) | -3.81 | -1.98 | -4.14 | -2.31 | -1.28 | DPS(Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Book NAV/Share(Rs) | -5.33 | -1.48 | 0.55 | 4.74 | 7.10 | Tax Rate(%) | 25.28 | 9.64 | 25.18 | 28.11 | 21.43 | Margin Ratios | | | | | | Core EBITDA Margin(%) | -36.02 | -6.34 | -24.45 | -15.56 | -11.14 | EBIT Margin(%) | -34.09 | -5.21 | -22.76 | -14.14 | -6.42 | Pre Tax Margin(%) | -49.92 | -12.36 | -28.37 | -21.25 | -8.82 | PAT Margin (%) | -37.30 | -11.17 | -21.23 | -15.28 | -6.93 | Cash Profit Margin (%) | -36.85 | -10.90 | -20.95 | -14.92 | -6.60 | Performance Ratios | | | | | | ROA(%) | -9.41 | -6.35 | -18.41 | -8.97 | -7.22 | ROE(%) | 0.00 | 0.00 | -158.64 | -39.93 | -17.00 | ROCE(%) | -25.63 | -8.08 | -73.05 | -21.87 | -10.70 | Asset Turnover(x) | 0.25 | 0.57 | 0.87 | 0.59 | 1.04 | Sales/Fixed Asset(x) | 0.28 | 0.77 | 1.87 | 2.59 | 14.05 | Working Capital/Sales(x) | -0.77 | -2.19 | -2.83 | -8.69 | 8.15 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 3.53 | 1.30 | 0.54 | 0.39 | 0.07 | Receivable days | 61.40 | 2.66 | 37.69 | 247.35 | 194.00 | Inventory Days | 154.12 | 115.80 | 139.46 | 180.65 | 35.26 | Payable days | 8.90 | 47.94 | 131.08 | 286.05 | 115.09 | Valuation Parameters | | | | | | PER(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | PCE(x) | -5.83 | -14.21 | -10.99 | -2.52 | -6.02 | Price/Book(x) | -4.16 | -18.98 | 83.21 | 1.23 | 1.08 | Yield(%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EV/Net Sales(x) | 3.53 | 2.38 | 2.50 | 0.24 | 0.69 | EV/Core EBITDA(x) | -10.48 | -48.10 | -11.12 | -1.74 | -11.29 | EV/EBIT(x) | -10.34 | -45.60 | -10.98 | -1.70 | -10.71 | EV/CE(x) | 0.97 | 0.97 | 2.54 | 0.14 | 0.50 | M Cap / Sales | 2.15 | 1.55 | 2.30 | 0.38 | 0.40 | Growth Ratio | | | | | | Net Sales Growth(%) | -43.09 | -8.14 | 27.68 | -20.10 | 140.37 | Core EBITDA Growth(%) | -287.70 | 79.82 | -108.19 | -80.90 | 22.05 | EBIT Growth(%) | -272.40 | 78.97 | -105.48 | -76.01 | 22.72 | PAT Growth(%) | -90.08 | 51.67 | -77.38 | -76.27 | -35.93 | EPS Growth(%) | -90.08 | 51.67 | -77.38 | -76.27 | -35.93 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | -3.05 | -12.18 | 11.56 | 0.15 | 1.05 | Current Ratio(x) | 0.38 | 0.65 | 0.53 | 0.92 | 1.12 | Quick Ratio(x) | 0.37 | 0.29 | 0.32 | 0.41 | 0.95 | Interest Cover(x) | -2.15 | -0.73 | -4.06 | -1.99 | -2.68 | Total Debt/Mcap(x) | 0.73 | 0.64 | 0.14 | 0.12 | 0.97 |
|
|
|
|
|
|